The team of Xiao Gengfu / Zhang Leiping of our office and the team of Shen Jingshan / Xie Yuanchao of Shanghai Institute of Materia Medica, Chinese Academy of Sciences found that the anti-new coronavirus drug VV116 also has the potential to treat respiratory syncytial virus infection

Respiratory syncytial virus (RSV) is a single-stranded, negative-strand, non-segmented RNA virus belonging to the family Paramyxoviridae and the genus Pneumovirus.

On April 16, 2022, Signal Transduction and Targeted Therapy published online a question completed by the team of Xiao Gengfu / Zhang Leiping from Wuhan Institute of Virology/State Key Laboratory of Virology, Chinese Academy of Sciences and the team of Shen Jingshan / Xie Yuanchao from Shanghai Institute of Materia Medica, Chinese Academy of Sciences .

In this study, the antiviral effects of 6 nucleoside analogs, including remdesivir nucleoside (GS-441524), remdesivir (RDV), and reported RSV inhibition, were first explored on 3 RSV-sensitive cell lines.

Figure 1.

At present, there are no preventive RSV vaccines and small-molecule specific drugs for the treatment of RSV infection

Zhang Ruxue , post-doctoral researcher of Wuhan Institute of Virology, Chinese Academy of Sciences , and Zheng Wei , doctoral student of Shanghai Institute of Materia Medica are the co-first authors.

Original link:

https://